Multiplatform serum metabolic phenotyping combined with pathway mapping to identify biochemical differences in smokers (NMR assay)

A multiplatform comparison of serum of smokers (n=56) and non-smokers (n=57) using NMR spectroscopy and UPLC-MS was carried out to determine perturbed biochemical functions associated with tobacco smoking. This should be helpful for establishing causal relationships between exposure and adverse events. The statistical modelling revealed clustering of the classes, distinguished by metabolic biomarkers. The identified metabolites were subjected to metabolic pathway enrichment, modelling adverse biological events using available databases. Perturbation of metabolites involved in COPD, cardiovascular diseases and cancer were identified. Combining multiplatform metabolic phenotyping with knowledge-based mapping gives mechanistic insights into disease development which can be applied to next-generation tobacco/ nicotine products for risk assessment.

NMR assay is reported in the current study MTBLS374.
UPLC-MS assay is reported in MTBLS364.